載入中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$42.67
+US$0.53 · +1.26%
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
前收盤價
US$42.67
+US$0.53 · +1.26%
盤中時間採用ET。市場資料可能有所延遲。
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
日內區間
目前US$42.67
52週區間
目前US$42.67
盤中時間採用ET。市場資料可能有所延遲。
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
日內區間
目前US$42.67
52週區間
目前US$42.67
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 7.19億 USD | 6.62億 USD | 6.08億 USD | 6.67億 USD | 5.8億 USD |
| 銷貨成本 | 7456.2萬 USD | 7790.6萬 USD | 8377.9萬 USD | 8722.1萬 USD | 7506.1萬 USD |
| 毛利 | 6.44億 USD | 5.84億 USD | 5.24億 USD | 5.8億 USD | 5.05億 USD |
| 研究與開發 | 1.06億 USD | 1.09億 USD | 9159.3萬 USD | 7455.2萬 USD | 9046.7萬 USD |
| 銷售、一般及管理費用 | 4.86億 USD | 3.36億 USD | 3.36億 USD | 3.77億 USD | 3.05億 USD |
| 營業費用 | 6.81億 USD | 5.02億 USD | 5.29億 USD | 5.34億 USD | 4.19億 USD |
| 利息收入 | 1325.3萬 USD | 1620.4萬 USD | 1045.3萬 USD | 2168.9萬 USD | 1056.9萬 USD |
| 利息支出 | — | — | 241.5萬 USD | 707萬 USD | 2342.3萬 USD |
| 折舊和攤銷 | 9156.3萬 USD | 8041.4萬 USD | 8485.9萬 USD | 8554.3萬 USD | 3259.5萬 USD |
| 營業利益 | −3686.4萬 USD | 8166.6萬 USD | −526.9萬 USD | 4612.4萬 USD | 8602.9萬 USD |
| 淨利 | −3855萬 USD | 7386.5萬 USD | 131.6萬 USD | 6071.1萬 USD | 5342.4萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$57.60
上漲空間 34.99%報告持有此股票曝險的交易所交易基金。
iShares Core S&P Small-Cap ETFIJR1.46億0.14%1031.91億 USD0.06%US$137.55+0.17%
Vanguard Morningstar Total Stock Market ETFVTI7764.47萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM6193.76萬0.08%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB5600.45萬0.03%1853億 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR3561.94萬0.05%682億 USD0.05%US$234.43+0.22%
Vanguard Extended Market ETFVXF2975.78萬0.03%954億 USD0.05%US$235+0.80%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM2255.01萬0.14%158.4億 USD0.03%US$53.45+0.17%
Dimensional - US Small Cap ETFDFAS1927.75萬0.06%338.69億 USD0.31%US$78.35+0.32%iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Value ETFVBRVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMDimensional - US Small Cap ETFDFASAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
